Alzheimer Disease Biomarkers and Assisted Dying | ClinicLens

This Viewpoint discusses the expansion of blood-based biomarker testing for Alzheimer disease and outlines patient-physician communication strategies for end-of-life questions and physician-assisted death.

Medical Literature · Updated 2026-08-10

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.